Skip to content

Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery. ( EpiGrid )

The EpiGrid Study Evaluation of New Flexible High-density Intra-operative ECoG Electrodes for Epilepsy Surgery

Status
Recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06205160
Acronym
EpiGrid
Enrollment
12
Registered
2024-01-12
Start date
2025-01-01
Completion date
2027-03-31
Last updated
2025-12-10

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Focal Epilepsy, Intraoperative Monitoring

Keywords

intra-operative electrocorticography, HFO, epileptic biomarkers, high frequency oscillations, epilepsy surgery, flexible ECoG, subdural electrode

Brief summary

The objective of this prospective interventional monocentric clinical investigation is to evaluate the feasibility and performance of the flexible high-density SOFT ECoG electrode grids, manufactured by Neurosoft Bioelectronics SA (test device; TD), in comparison to regular high-density electrode grids (ADTech, CE-marked) (control device; CD) routinely used at the investigation site during epilepsy surgery. Subjects will undergo ≥ 2 additional intracranial recordings pre- and post-resection with the TD next to the standard recordings with the CD during ECoG-tailored epilepsy surgery.

Interventions

DEVICESOFT ECoG subdural grid electrode

Test Device (SOFT ECoG subdural grid electrode): used for recording. During epilepsy surgery, in addition to standard clinical protocol (recording with comparator device), subjects will undergo ≥ 2 additional intracranial recordings with the SOFT ECoG flexible high density electrode grid (TD). Recording will be registered pre- and post-resection. All procedures will be conducted according to standard clinical practice. Any medical decision making will be done using the standard of care CE-marked device (CD). The investigational, non-CE marked device is not used for clinical decision making.

Sponsors

UMC Utrecht
CollaboratorOTHER
European Research Council
CollaboratorOTHER
Neurosoft Bioelectronics SA
Lead SponsorINDUSTRY

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Age ≥18 years at the time of enrolment * Lesional epilepsy (incl. secondary mesial temporal sclerosis) that is considered a candidate for intra-operative high-density grid recordings (incl. patients who underwent sEEG preceding resective surgery) * Provided informed consent for study participation by the subject

Exclusion criteria

* Occipital lesion * Surgeries involving a primary mesial temporal lesion, a disconnection, or hemispherectomy. * Planned ioECoG recordings during fully awake surgery and/or functional recordings * Use of anticoagulants that cannot be discontinued during the perioperative period, or a factor XIII deficiency or any other haematological disease * Active participation in another investigational device study * Any other condition that in the opinion of the investigator may adversely affect the safety of the subject or would limit the subject's ability to complete the study. * Insufficient understanding of Dutch language.

Design outcomes

Primary

MeasureTime frameDescription
Background SNR pre-resection recordingup to 24 hoursPerformance in terms of signal quality is assessed via background signal to noise ratio (SNR). Only channels which record properly based on visual inspection (no noise, no flat line) will be included in the background SNR calculation. For the pre-resection recordings (SITUATION I/I\*), the background SNR per (included) channel and the average SNR for the electrode grid will be calculated, and pairwise comparison will be conducted between TD (SITUATION I\*) and CD (SITUATION I).

Secondary

MeasureTime frameDescription
Usability evaluationup to 48 hoursA (digital) usability questionnaire (system usability scale + open questions) will be collected (within 48h after surgery).
Electrode deficiency ratio (%)up to 24 hoursThe individual electrodes will be classified, per recording, as poor or good signal quality based on visual criteria (i.e., noise, flat signal due to overlap with resection cavity or silicone of secondary electrode strip, pulsation artifacts). As a result, an electrode deficiency ratio (%) will be calculated as follows: # bad electrodes divided by the total # of electrodes per recording. This will be determined for the similar positioned CD recording (SITUATION I/II) to allow comparison with the TD (SITUATION I\*/I\*\*).
Epileptic biomarker identification ( eg. number of spikes/HFOs per min, event SNR)up to 24 hoursAfter the surgery, spikes and high frequency oscilations (HFOs) will be visually marked in the final minute of the recording (note: assisted by automated spike/HFO detector) and checked by an expert. Marking of spikes and HFOs will be done in the TD and the corresponding CD recordings pre- and post-resection. Event rates (number of spikes/HFOs per minute) per channel and total per recording will be compared between the TD and CD. The average event SNR per channel and the average SNR per epileptogenic event type will be calculated per recording. The event SNR will be compared between the CD recording (SITUATION I/II) and the TD (SITUATION I\*/I\*\*).
Background SNR of post-resection recordingsup to 24 hoursThe background SNR for post-resection recordings (SITUATION II/II\*\*) will be computed and pairwise compared. Note that it shall be considered that for the post-resection recordings (SITUATION II/II\*\*), in particular when measuring near/in the resection cavity, the performance of both the TD and CD for electrode deficiencies might differ significantly, positively and negatively.
Surgical complications (e.g. SAEs/SADEs)up to hospital discharge, on average at 10 daysThe safety analysis will include surgical complications in terms of device deficiencies (DDs) and serious adverse events (SAEs), and whether these are device related (SADEs).

Countries

Netherlands

Contacts

Primary ContactKarolina Janikowska Clinical Affairs Manager, PhD
karolina.janikowska@neurosoft-bio.com000 000-0000
Backup ContactG.J.M. Zijlmans Study Principal Investigator, PhD
G.J.M.Zijlmans@umcutrecht.nl000 000-0000

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026